Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.

Blood cancer journal·2024
Same author

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.

Leukemia·2021
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Leukemia·2017
Same author

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Blood cancer journal·2017
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Targeting bone in myeloma.

G J Morgan1, Ping Wu

  • 1Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK. gareth.morgan@icr.ac.uk

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|February 7, 2012
PubMed
Summary
This summary is machine-generated.

Myeloma bone disease impacts survival and requires targeting bone cell interactions. Bone-targeted therapies improve outcomes by inhibiting myeloma growth and survival.

More Related Videos

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

Related Experiment Videos

Last Updated: May 25, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

Area of Science:

  • Oncology
  • Bone Biology
  • Cancer Therapeutics

Background:

  • Myeloma bone disease (BD) significantly impairs patient quality of life and survival.
  • The progression of BD involves increased osteoclastogenesis and suppressed osteoblastogenesis, crucial for myeloma tumor growth.
  • Myeloma cell survival and expansion are intrinsically linked to interactions with bone microenvironment.

Purpose of the Study:

  • To summarize recent advancements in understanding the biology of myeloma bone disease.
  • To highlight the roles of osteoclasts and osteoblasts in myeloma bone disease pathogenesis.
  • To discuss therapeutic strategies targeting myeloma-bone interactions.

Main Methods:

  • Review of experimental and clinical findings on myeloma bone disease.
  • Analysis of biological mechanisms underlying myeloma-bone interactions.
  • Exploration of therapeutic targeting of bone-modifying cells.

Main Results:

  • Bone-targeted therapies demonstrate efficacy in improving myeloma bone disease.
  • These therapies create an unfavorable environment for myeloma cell growth and survival.
  • Targeting bone cell dysregulation offers a dual benefit for myeloma treatment.

Conclusions:

  • Understanding myeloma-bone interactions is key to developing novel treatments for BD.
  • Therapeutic strategies focused on bone elements can improve clinical outcomes for myeloma patients.
  • Further research into these mechanisms will facilitate improved patient prognosis.